Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | PD-L1 inhibitors in r/r Hodgkin lymphoma

Ryan Lynch • 13 Dec 2021
ASH 2021
Hodgkin Lymphoma Lymphoma Antibodies Checkpoint inhibitors Nivolumab Pembrolizumab

Ryan Lynch, MD, Seattle Cancer Care Alliance, University of Washington, Seattle, WA, describes current treatment options for patients with relapsed/refractory Hodgkin lymphoma who have progressed or are ineligible for transplant. Whilst PD-L1 inhibitors such as pembrolizumab and nivolumab have shown to efficacious in patients, producing durable responses remains a barrier. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Ryan Lynch

0:55
Mosunetuzumab in untreated FL and MZL: a response-adapted trial
Ryan Lynch • 8 Dec 2023
1:15
Polatuzumab vedotin combined with chemotherapy in untreated large B-cell lymphoma
Ryan Lynch • 8 Dec 2023
1:31
Pembrolizumab plus AVD in cHL: long-term follow-up of a Phase II study
Ryan Lynch • 8 Dec 2023
1:09
Update on parsaclisib in patients with R/R FL treated in the CITADEL-203 trial
Ryan Lynch • 8 Dec 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals